Oncotype DX® Breast Recurrence Score: Invasive Breast Cancer

The Oncotype DX Breast Recurrence Score test is a diagnostic test performed on a tumor pathology slide after a breast cancer surgery or biopsy. This genomic test studies 21 genes in your cancer and identifies characteristics that allow cancer to grow or be aggressive.

Oncotype DX testing results provide information enables a physician to customize and recommend the most appropriate treatments based on the biology of your tumor. The test reports if you would benefit from chemotherapy or if hormonal therapy alone would effectively treat your cancer and predicts the risk of future distant recurrence.

The goal of Oncotype DX Breast Recurrence testing is to facilitate treatment planning based on an individual's tumor biology to determine if the patient will benefit from chemotherapy.

Invasive Breast Cancer Criteria:

- Recently diagnosed with invasive breast cancer
- Potential candidate for chemotherapy
- Cancer stage I, II or IIIa
- Estrogen-receptor positive (ER+) tumor
- HER2 negative (HER2-) tumor
- 1 to 3 positive nodes

How the Test is Performed

You do not have to undergo any additional testing or procedures. A tumor pathology slide prepared during surgery (biopsy, lumpectomy or mastectomy) is shipped for testing.

Oncotype DX Recurrence Score® Report

Results of the test are returned to the physician with a Recurrence Score from 0 to 100.

Clinical studies have provided physicians additional information about the benefit of chemotherapy based on the age of patients:

- **Patients Older Than 50 Years:**
  - 0 - 25: No benefit from chemotherapy
  - 26 – 100: Substantial benefit from chemotherapy
- **Patients Younger Than 50 Years:**
  - 0 - 15: No benefit from adding chemotherapy
  - 16 - 20: 1.6% benefit from adding chemotherapy
  - 21 - 25: 6.5% benefit from adding chemotherapy
  - 26 - 100: Substantial benefit from chemotherapy

Patients with lower Recurrence Scores have a lower risk that their cancer will return. However, it is important to note that a lower Recurrence Score does not mean that there is no chance that a woman's cancer will return. The test analyzes the genes and serves as a prediction, not an absolute fact. The results are based on the latest scientific methods known in determining cancer treatment appropriateness.

Knowing the genomic profile of a cancer allows your physician to plan and tailor a treatment plan for you and your cancer. Ask your physician if you are a potential candidate for the test if you have early stage breast cancer.

Additional Information:

_____

_____

_____